GILD

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 9

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,368

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F4 · price: Sales prices for the transactions reported here range from $117.91 to $118.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 8

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,168

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sales prices for the transactions reported here range from $118.91 to $119.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or the shareowners upon request.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 7

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 6

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,168

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sales prices for the transactions reported here range from $117.91 to $118.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,168

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sales prices for the transactions reported here range from $118.91 to $119.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or the shareowners upon request.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,168

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sales prices for the transactions reported here range from $117.91 to $118.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0000882095-25-000037 · wk-form4_1755564959.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001310204-25-000005 · wk-form4_1755560041.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,110

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-019732 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 605,725

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F3 · price: Sale prices reported for the transactions reported here range from $113.71 to $114.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-019732 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 614,070

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F2 · price: Sale prices reported for the transactions reported here range from $112.71 to $113.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-019654 · form4.xml · derivative · entry 5

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,646

Underlying: Common Stock · 8,229 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F3 · derivative.exercise_date: The restricted stock units have a three-year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested.

F3 · derivative.expiration_date: The restricted stock units have a three-year vesting schedule. 33.33% will vest on each yearly anniversary of the date of the grant until fully vested.

SEC source: 0001127602-25-019654 · form4.xml · derivative · entry 4

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,875

Underlying: Common Stock · 514 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,721

SEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,544

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-019654 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,315

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-019286 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,610

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-019291 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,168

F1 · kind: The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001127602-25-019182 · form4.xml · derivative · entry 3

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,665

Underlying: Common Stock · 5,000 shares

Expires 2031-05-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting.

SEC source: 0001127602-25-019182 · form4.xml · nonDerivative · entry 2

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,920

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

SEC source: 0001127602-25-019182 · form4.xml · nonDerivative · entry 1

Bluestone Jeffrey · CIK 0001771814 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,920

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

SEC source: 0001127602-25-018401 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 615,725

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F3 · price: Sale prices reported for the transactions reported here range from $111.03 to $111.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-018401 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 616,325

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F2 · price: Sale prices reported for the transactions reported here range from $110.03 to $111.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-017689 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,168

F1 · kind: The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001127602-25-017692 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,110

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001127602-25-017331 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,915

Underlying: Common Stock · 3,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017331 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,610

SEC source: 0001127602-25-017331 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-017333 · form4.xml · derivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,923

Underlying: Common Stock · 10,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017333 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 625,725

SEC source: 0001127602-25-017333 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,693

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-017335 · form4.xml · derivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,360

Underlying: Common Stock · 3,843 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017335 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,168

SEC source: 0001127602-25-017335 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-017337 · form4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,389

Underlying: Common Stock · 1,313 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017337 · form4.xml · nonDerivative · entry 2

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,801

SEC source: 0001127602-25-017337 · form4.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · EVP, Corporate Affairs & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-017339 · form4.xml · derivative · entry 3

Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,785

Underlying: Common Stock · 920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-017339 · form4.xml · nonDerivative · entry 2

Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,676

SEC source: 0001127602-25-017339 · form4.xml · nonDerivative · entry 1

Wilfong Diane E. · CIK 0001374988 · Interim Corp Controller & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001127602-25-016281 · form4.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 620,268

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F3 · price: Sale prices reported for the transactions reported here range from $110.68 to $111.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-016281 · form4.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 623,852

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F2 · price: Sale prices reported for the transactions reported here range from $109.68 to $110.67. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-015457 · form4.xml · derivative · entry 7

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,110

Underlying: Common Stock · 12,500 shares

Expires 2029-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F5 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-015457 · form4.xml · derivative · entry 6

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,610

Underlying: Common Stock · 12,500 shares

Expires 2029-07-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F5 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001127602-25-015457 · form4.xml · nonDerivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,152

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F4 · price: Sale prices reported for the transactions reported here range from $107.16 to $107.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-015457 · form4.xml · nonDerivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,152

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F3 · price: Sale prices reported for the transactions reported here range from $106.96 to $107.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-015457 · form4.xml · nonDerivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001127602-25-015457 · form4.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,152

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

F2 · price: Sale prices reported for the transactions reported here range from $107.06 to $107.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

SEC source: 0001127602-25-015457 · form4.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.